Fapon Showcases Groundbreaking Enzyme Innovations at AMP 2026 Event

Fapon, a leader in life sciences, recently participated in the 2026 Association for Molecular Pathology (AMP) Annual Meeting and Expo, held from November 10th to 14th at the Seattle Convention Center. At Booth 1905, Fapon highlighted significant advancements in enzyme technology, showcasing AI-engineered enzymes and application-specific reverse transcription methodologies that cater to the evolving landscape of molecular diagnostics.

A standout moment during Fapon's presence at the conference was a workshop titled "Unlocking the Full Potential of Enzymes in Molecular Diagnostics". This session took place on November 11th and featured various expert perspectives on enzyme engineering, providing insights into real-world applications of enzyme innovations. Attendees learned how advancements in enzyme design can enhance performance across several diagnostics platforms, including qPCR, RT-qPCR (reverse transcription quantitative polymerase chain reaction), NGS (next-generation sequencing), and isothermal amplification.

Dr. Ning Wu from Fapon presented a comprehensive overview of the company’s enzyme engineering platform, which uniquely combines AI-driven design processes with high-throughput experimental validation. This iterative approach means that experimental outcomes are continuously fed back into the modeling process to refine candidate selections for further design iterations. For instance, after just two rounds of engineering, Fapon's AI-optimized MMLV reverse transcriptases have shown the capability to generate complementary DNA (cDNA) from RNA templates extending up to 9 kb in length at optimized temperatures of 60°C.

In addition, the workshop introduced TeloScript II, a next-generation reverse transcriptase specifically crafted to facilitate full-length cDNA synthesis for long-read sequencing applications—even when dealing with RNA templates that present complex secondary structures. An invited expert also shared insights from a comprehensive study using full-length transcriptomics that underscored how long-read sequencing techniques can unravel intricate fusion genes and transcript isoforms. These discussions highlighted the importance of reverse transcription efficiency in supporting high-demand RNA sequencing workflows.

Throughout the convention, Fapon showcased several noteworthy enzyme products developed via their distinctive AI-driven design approach, further complemented by experimental validation. Among the highlighted products was ProPrime II Taq DNA Polymerase, a second-generation hot-start polymerase characterized by its speed and resistance to inhibitors. This polymerase allows for the completion of formula-specific quadruplex qPCR cycles in just under 20 minutes, demonstrating its efficiency for multiplexed assays and near-patient testing methodologies.

Another notable product was the MeloScript III WS Reverse Transcriptase, designed for one-step RT-qPCR applications. Like ProPrime II, it is equipped with high inhibitor resistance capabilities, maintaining reverse transcription performance after exposure to heat up to 64°C for a full ten minutes. The enzyme’s unique lyophilization-ready format makes it applicable for near-patient assay formats and lyophilized reagents.

Fapon also presented additional enzyme solutions tailored for specific applications, including the PreciAmp HS RT designed for RT-LAMP applications, and VeloScript I for NGS workflows. The PreciAmp HS RT is engineered to maintain performance even in the presence of common inhibitors like ethanol and various viral preservation solutions. Meanwhile, VeloScript I excels in synthesizing full-length cDNA up to 15 kb, showcasing its effectiveness with diverse RNA input quantities while tackling the challenges posed by complex RNA secondary structures.

Fapon showcased the NK081 Poly(A) mRNA Magnetic Isolation Module as another product designed to purify mRNA, achieving over 95% removal of rRNA in under 40 minutes. Complementing this was the NextGen Universal FS DNA Library Prep Kit, which can complete library preparation in under an hour, widening Fapon's portfolio of RNA and DNA sample preparation solutions.

The company used its presence at AMP 2026 as a strategic opportunity to connect with molecular pathology researchers, assay developers, and in vitro diagnostic manufacturers. Through vibrant discussions, they explored the emerging needs of applications and technical obstacles facing the industry. Fapon welcomed close interactions with community members, fostering collaborations to leverage their innovative enzyme technologies and comprehensive workflow solutions.

Fapon expressed gratitude to all visitors and participants at their booth and workshop. The company looks forward to ongoing discussions aimed at advancing molecular diagnostics through its innovative enzyme technologies. For further information about Fapon’s solutions in molecular diagnostics, interested parties can contact them via email or through their website. Fapon is committed to pioneering advancements in health management, covering the entire lifecycle of diagnostics and therapeutics, with offerings reaching over 70 countries and more than 2,500 partners worldwide.

With a focus on transforming life sciences, Fapon continues to push the boundaries of research and development, integrating AI-driven initiatives to redefine how diagnostics and therapeutics are discovered and delivered—fostering a brighter, healthier future for all.

Topics Consumer Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.